Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Immunotherapy, a new therapeutic area to destroy tumor cells

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

31 Oct 2009

NYBC and its divisions call upon the community to join the fight against cancer by donating blood

November is both Pancreatic Cancer Awareness Month and Lung Cancer Awareness Month, and New York Blood Center (NYBC) and its divisions in Manhattan, Long Island, Hudson Valley, Brooklyn/Staten Island, and New Jersey call upon the community to join the fight against cancer by donating blood today.

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Recent releases in Global Health

"Action always leads to reaction, a fundamental law of nature," write the authors of an introduction appearing in a Journal of Acquired Immune Deficiency Syndromes (JAIDS) supplemental issue that focuses on global health systems.

30 Oct 2009

Participation in clinical trials may offer better prognosis for patients with chronic heart failure

Patients with chronic heart failure who agree to take part in clinical trials have a better prognosis than those who do not, according to a study reported in the November European Journal of Heart Failure.

30 Oct 2009

Hard to Treat Diseases negotiating possible merger with EU based stem cell research company

Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.

30 Oct 2009

Unaudited consolidated financial results for the third-quarter reported by AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.

29 Oct 2009

National study to prevent strokes in children and adolescents with sickle cell anemia

St. Jude Children's Research Hospital investigators were recently awarded a $23 million federal grant to launch a national study of the drug hydroxyurea to prevent first strokes in children and adolescents with sickle cell anemia (SCA).

29 Oct 2009

Iron-folic acid supplements during pregnancy can reduce offspring’s mortality rate

Offspring whose mothers had been supplemented with iron-folic acid during pregnancy had dramatically reduced mortality through age 7, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

29 Oct 2009

Moores UCSD Cancer Center awarded $20 million for cancer research

Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

OrSense launches a non-invasive Hb measurement system for anemia screening

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today at the American Association of Blood Banks (AABB) Annual Meeting & TXPO, at New Orleans, the presentation of NBM-200, a non-invasive hemoglobin (Hb) measurement system for anemia screening in blood donation centers.

27 Oct 2009

Detecting the cause of occult gastrointestinal bleeding with the PillCam SB video capsule demonstrated

Given Imaging Ltd. today announced that new data presented at the American College of Gastroenterology (ACG) 2009 Conference show that by visualizing the small bowel with the PillCam® SB video capsule, physicians can detect the cause of occult gastrointestinal bleeding (OGIB) and adapt how they manage and treat these patients.

27 Oct 2009

Video capsule endoscopy is safe for patients with heart devices

A new Mayo Clinic study suggests that video capsule endoscopy (CE), a procedure that uses wireless technology in diagnosing intestinal disease, is safe for patients with heart devices. Wireless electrical gadgets, such as cell phones, have been shown to interfere with implanted heart devices, including pacemakers and defibrillators. This risk has led medical experts to speculate that capsule endoscopy could similarly cause heart devices to fail.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Medgenics is pleased to announce that it has signed a preclinical development and option agreement with a major international biopharmaceutical company that is a market leader in the field of hemophilia.

23 Oct 2009

ADA supports IOM’s proposal on school nutrition programs

The American Dietetic Association welcomes a report issued Wednesday, October 21, by the Institute of Medicine encouraging federal school meal programs to adopt standards that increase the nutrition content and limit the calories in meals served to schoolchildren.

23 Oct 2009

Affymax to make multiple presentations on preclinical and clinical data of Hematide

Affymax, Inc. today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego.

23 Oct 2009

Anemia News and Research

Further Reading

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Immunotherapy, a new therapeutic area to destroy tumor cells

NYBC and its divisions call upon the community to join the fight against cancer by donating blood

Data from multiple clinical and preclinical studies evaluating Hematide announced

Recent releases in Global Health

Participation in clinical trials may offer better prognosis for patients with chronic heart failure

Hard to Treat Diseases negotiating possible merger with EU based stem cell research company

Unaudited consolidated financial results for the third-quarter reported by AMAG Pharmaceuticals

National study to prevent strokes in children and adolescents with sickle cell anemia

Iron-folic acid supplements during pregnancy can reduce offspring’s mortality rate

Moores UCSD Cancer Center awarded $20 million for cancer research

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

New CCS guidelines and position papers for physicians and nurse practitioners

OrSense launches a non-invasive Hb measurement system for anemia screening

Detecting the cause of occult gastrointestinal bleeding with the PillCam SB video capsule demonstrated

Video capsule endoscopy is safe for patients with heart devices

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

ADA supports IOM’s proposal on school nutrition programs

Affymax to make multiple presentations on preclinical and clinical data of Hematide

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News